CMPX_OUT_1 [2025-04-01 04:49:35 -0400] 2295 Bytes | 639 tokens | Cum: 639 tkns (7.99% of 8k)
==========================================================================

Booyah, my friends! It's already 4:49:35 AM on Tue Apr 01, 2025 -0400, and I've got my eyes locked on Compass Therapeutics (CMPX), pushing up to 2.18 from 1.9. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for Compass Therapeutics:

C1 - Mar-31-25 04:05PM - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
C2 - Mar-27-25 10:20AM - Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5?
C3 - Mar-02-25 10:22AM - Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
C4 - Feb-27-25 08:00AM - Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
C5 - Jan-29-25 08:00AM - Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
C6 - Jan-08-25 08:00AM - Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
C7 - Dec-10-24 08:00AM - Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
C8 - Dec-02-24 08:00AM - Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Prior AI Reports for CMPX:
1. 2025-03-31 – Score: 52 – Target: 2.8500 – Highs: 1.9900 / – / –
despite-recent-slump-insider-confidence-suggests-potential-turnaround

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Compass Therapeutics (CMPX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CMPX_OUT_3 [2025-04-01 04:49:36 -0400] 1098 Bytes | 338 tokens | Cum: 979 tkns (12.24% of 8k)
==========================================================================

Showing C1 (chunk 1 of 3): C1:
**Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer**
Date: Mar-31-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052773/0/en/Compass-Therapeutics-to-Host-Webcast-Highlighting-Top-Line-Clinical-Data-from-the-Ongoing-Randomized-Phase-2-3-Study-Evaluating-Tovecimig-in-Patients-with-Biliary-Tract-Cancer.html

March 31, 2025 16:05 ET| Source:Compass TherapeuticsCompass Therapeutics

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_5 [2025-04-01 04:49:37 -0400] 1039 Bytes | 286 tokens | Cum: 1267 tkns (15.84% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A2 - 2025-03-31T20:14:23Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...
A3 - 2025-03-31T20:05:00Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...
A4 - 2025-03-31T20:20:44Z - Compass Therapeutics (CMPX) to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Ran...
A5 - 2025-03-31T20:16:23Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CMPX_OUT_7 [2025-04-01 04:49:45 -0400] 1098 Bytes | 337 tokens | Cum: 1606 tkns (20.08% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adverum Biotechnologies (NASDAQ:ADVM)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44573149/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers bioAffinity Technologies BIAF stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. Nutex Health NUTX shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. Compass Therapeutics CMPX stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. Plus Therapeutics PSTV stock moved upwards by 17.7% to $1.13. The market value of their

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_9 [2025-04-01 04:49:46 -0400] 829 Bytes | 253 tokens | Cum: 2028 tkns (25.35% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-04T13:08:00Z - Top 3 High-Momentum Companies Analysts Are Still Bullish On
B2 - 2024-09-03T12:00:00Z - Compass Therapeutics to Participate in Upcoming Investor Events
B3 - 2024-08-26T11:00:00Z - Eliem Therapeutics Announces Additions to its Leadership Team
B4 - 2024-08-07T12:00:00Z - Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
B5 - 2024-05-30T12:00:00Z - Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
B6 - 2024-05-28T20:10:00Z - Compass Therapeutics Announces CEO Transition

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CMPX_OUT_11 [2025-04-01 04:49:48 -0400] 657 Bytes | 172 tokens | Cum: 2202 tkns (27.52% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Top 3 High-Momentum Companies Analysts Are Still Bullish On**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/top-3-highmomentum-companies-analysts-are-still-bullish-on-200656960Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_13 [2025-04-01 04:49:48 -0400] 812 Bytes | 195 tokens | Cum: 2439 tkns (30.49% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-27 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper.

Unless otherwise stated or the context otherwise indicates, references to the Company , we , our , us or similar terms refer to Compass Therapeutics, Inc. together with its wholly-ow...

S2 - 2025-02-27 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper.

Unless otherwise stated or the context otherwise indicates, references to the Company , we , our , us or similar terms refer to Compass Therapeutics, Inc. together with its wholly-ow...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CMPX_OUT_15 [2025-04-01 04:49:54 -0400] 1098 Bytes | 228 tokens | Cum: 2669 tkns (33.36% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations.

Unless otherwise stated or the context otherwise indicates, references to the Company , we , our , us or similar terms refer to Compass Therapeutics, Inc. together with its wholly-owned subsidiaries, which we refer to as Compass Therapeutics.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included in this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading Special Note Regarding

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_17 [2025-04-01 04:50:00 -0400] 1098 Bytes | 230 tokens | Cum: 3004 tkns (37.55% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): Forward-Looking Statements elsewhere in this Form 10-K. You should review the disclosure under the heading Risk Factors in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via a

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_19 [2025-04-01 04:50:04 -0400] 1098 Bytes | 220 tokens | Cum: 3334 tkns (41.68% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ctivators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.

Financial Overview

Since our inception, we have devoted substantially all of our efforts to organizing and staffing our Company, business planning, raising capital, research and development activities, building our intellectual property portfolio and providing general and administrative support for these operations. We have funded our operations primarily with proceeds from the sale of equity securities of $430 million through December 31, 2024.

We have incurred significant operating losses since inception. We have not generated an

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPX_OUT_21 [2025-04-01 04:50:16 -0400] 5400 Bytes | 1604 tokens | Cum: 5020 tkns (62.75% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 1,565,810 | Perf Month: -34.48% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 1.53M | Perf Quarter: 25.00% | Short Float: 5.71% | ROE: -36.07% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.02 | Index: RUT | Short Ratio: 3.00 | ROI: -37.54% |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 30.33 | Market Cap: 262.74M | Short Interest: 4.61M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.21 | Shs Outstand: 137.82M | Beta: 1.18 | EPS Surprise: -12.13% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -19.55% | Shs Float: 80.70M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -32.64% | Inst Own: 38.87% | Sales past 5Y: 0.00% | Earnings: Feb 27 BMO |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 5.85% | Insider Own: 41.64% | Employees: 35 | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -19.83% | Insider Trans: 0.00% | Debt/Eq: 0.05 | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Compass Therapeutics, Inc. (CMPX) by GORDON CARL L (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by Shin Barry (CFO) on 2025-02-11
- Stock Option (Right to Buy): 250000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2025-02-11
- Stock Option (Right to Buy): 1500000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by LINDAHL RICHARD S (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by Lerner Neil (SVP, CAO) on 2025-02-11
- Stock Option (Right to Buy): 200000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by GRAY MARY ANN (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by Ferneau Philip (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)

Inside Trans: Compass Therapeutics, Inc. (CMPX) by Chiniara Ellen (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -10481000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.9
Average Volume: 893923.57
30-Day High: 2.78
30-Day Low: 1.9

[Detailed Financials: Q3 2024]
- Total Assets: $149,151,000.0
- Total Liabilities: $10,753,000.0
- Total Equity: $138,398,000.0
- Current Assets: $141,140,000.0
- Current Liabilities: $4,433,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.08

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $17,965,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $155,611,000.0
- Total Liabilities: $9,507,000.0
- Total Equity: $146,104,000.0
- Current Assets: $153,546,000.0
- Current Liabilities: $9,507,000.0

[Income Statement: Q2 2024]
- Revenue: $850,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-4,270,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CMPX_OUT_23 [2025-04-01 04:50:18 -0400] 676 Bytes | 167 tokens | Cum: 5461 tkns (68.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CMPX_IN_25 [2025-04-01 04:50:18 -0400] 126 Bytes | 29 tokens | Cum: 5518 tkns (68.97% of 8k)
==========================================================================

====================================
[2025-04-01 04:50:18] # Analysis Completed
Elapsed Time: 43.66 seconds